玮俊生物科技（股票代码：00660）于2026年7月7日发布公告，披露公司完成一笔金额为100万港元的可换股债券转股，并按每股0.01港元的发行价格增发16,666,666股普通股，折合约1666.67万股，占本次发行前公司已发行股本的4.53%。
本次增发完成后，公司已发行股本由原先的367,643,119股增至384,309,785股，库藏股份数保持为零。公告显示，此次发行已获公司董事会正式授权，并遵循了香港联合交易所证券上市规则及相关法律法规。公告最后由董事林家俊签署。
玮俊生物科技（股票代码：00660）于2026年7月7日发布公告，披露公司完成一笔金额为100万港元的可换股债券转股，并按每股0.01港元的发行价格增发16,666,666股普通股，折合约1666.67万股，占本次发行前公司已发行股本的4.53%。
本次增发完成后，公司已发行股本由原先的367,643,119股增至384,309,785股，库藏股份数保持为零。公告显示，此次发行已获公司董事会正式授权，并遵循了香港联合交易所证券上市规则及相关法律法规。公告最后由董事林家俊签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.